Brief: Nervgen Pharma Reports Positive Topline Data From The Chronic Cohort Of Its Phase 1B/2A Clinical Trial Evaluating Nvg-291 In Spinal Cord Injury
02/06/2025 13:30
June 2 (Reuters) - NervGen Pharma Corp NGEN.V: NERVGEN PHARMA REPORTS POSITIVE TOPLINE DATA FROM THE CHRONIC COHORT OF ITS PHASE 1B/2A CLINICAL TRIAL EVALUATING NVG-291 IN SPINAL CORD INJURY NERVGEN PHARMA CORP: STUDY MET ITS PRIMARY ENDPOINT BY ACHIEVING STATISTICAL SIGNIFICANCE ON ONE OF ITS TWO PRE-SPECIFIED CO-PRIMARY ENDPOINTS Source text: ID:nGNX2Yj0n0 Further company coverage: NGEN.V ((Reuters.Briefs@thomsonreuters.com;))